Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

38.55 -0.41 (-1.05%)
Official Closing Price Updated: 7:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,728,344
Open 38.80
Bid (Size) 38.40 (1)
Ask (Size) 39.84 (3)
Prev. Close 38.96
Today's Range 38.38 - 38.84
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a March 2025 decision expected. Trials showed better efficacy than... 
Via Benzinga
Exposures Product Safety

Performance

YTD
+2.77%
+2.77%
1 Month
-7.38%
-7.38%
3 Month
-2.13%
-2.13%
6 Month
-5.03%
-5.03%
1 Year
+8.35%
+8.35%

More News

Read More
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
Via Benzinga
2 Best Artificial Intelligence Stocks to Buy in October
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Via Benzinga
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
Via Benzinga
Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy'
Via Benzinga
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
From GSK plc
Via Business Wire
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Via Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Via Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Via Benzinga
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
Via MarketBeat
Topics Economy
Exposures Interest Rates
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.